Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris

Inclusion Criteria:

• Patients who are 12 years or older (unless minors are not permitted as per localregulations) who have been prescribed clindamycin phosphate 1.2% / adapalene 0.15% /benzoyl peroxide 3.1% gel as per the product monograph as part of routine clinicalcare for acne vulgaris but have not yet initiated treatment. The decision toprescribe clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gelmust be made prior to and independent of study participation.

• Patients and legally authorized representatives who are willing to provide writteninformed consent using an Institutional Review Board (IRB) or Independent EthicsCommittee (IEC)-approved Informed Consent Form (ICF) in English or French. Patientswho are less than the age of consent must sign an assent for the study and a parent,or a legal guardian must sign the informed consent.

• Patients who can read, understand, and communicate in English or French.

Patients must also meet the following additional inclusion criterion at the time of clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel initiation in order to be eligible for enrolment in the study:

• Patients have completed IRB or IEC-approved baseline ePROs (DermSat-7 and HUI2)after providing consent and prior to receiving their first dose of clindamycinphosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel.

• Patients have initiated clindamycin phosphate 1.2% / adapalene 0.15% / benzoylperoxide 3.1% gel within 5 days of signed informed consent/assent.

Exclusion Criteria:

• Patients who have a contraindication to clindamycin phosphate 1.2% / adapalene 0.15% / benzoyl peroxide 3.1% gel as per the product monograph:

1. Patients who are hypersensitive to clindamycin phosphate, to adapalene, tobenzoyl peroxide or to any ingredient in the formulation or component of thecontainer,

2. Patients with a history of regional enteritis (Crohn's disease), ulcerativecolitis, or antibiotic-associated colitis, and/or

3. Pregnant women and women planning a pregnancy.

• Patients who, at the time of informed consent, are clear or almost clear (Investigator Global Assessment [IGA] = 0 or 1) or are on current acne therapy (topical or systemic, etc.)), or undergoing procedures (e.g., laser, photodynamictherapy) that could impact study results, as per the investigator's judgement.

• Patients who have any other serious and/or uncontrolled medical condition, and/orare receiving any medical therapy, that prohibits the patient from participating asper the investigator's judgement.

• Patients who have whey protein-triggered acne, drug-induced acne, occupational acne,acne associated with hidradenitis suppurativa or synovitis, acne, pustulosis,hyperostosis, and osteitis (SAPHO) syndrome, or acne related to hyperandrogenicstates including polycystic ovary syndrome (PCOS).

• Patients who have conditions that mimic acne, including rosacea, folliculitis,perioral dermatitis, demodicosis.

• Patients who are not willing or able to complete electronic patient reportedoutcomes (ePROs) using an electronic device.